Fenoverine

Summary

Fenoverine (CHEMBL1512949) is a phase-3 clinical-stage small molecule (ATC A03AX05); indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A03AX05
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 459.6 Da · C26H25N3O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1512949
Name	Fenoverine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	72098
ATC	A03AX05
Molecular formula	C26H25N3O3S
Molecular weight	459.6
InChIKey	UBAJTZKNDCEGKL-UHFFFAOYSA-N

SMILES: C1CN(CCN1CC2=CC3=C(C=C2)OCO3)CC(=O)N4C5=CC=CC=C5SC6=CC=CC=C64

IUPAC name: 2-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]-1-phenothiazin-10-ylethanone

Also known as: Fenoverina, Fenoverine, Spasmopriv, SID29216372, SID144205534, SID170466194, FENOVERINE, fenoverine

Patent coverage: 143 distinct patent families (587 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 583 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: 4’-phosphopantetheinyl transferase ffp.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01507922	PHASE4	COMPLETED	Comparative Efficacy and Safety of Fenoverine

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).